Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.900
-0.200 (-4.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.890
-0.010 (-0.26%)
After-hours: Apr 28, 2026, 7:33 PM EDT
Orchestra BioMed Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 33.48 | 2.64 | 2.76 | 3.53 | -0.78 | |
| Revenue Growth (YoY) | 1169.22% | -4.42% | -21.88% | - | - | |
| Cost of Revenue | 0.19 | 0.2 | 0.19 | 0.21 | 0.2 | |
| Gross Profit | 33.29 | 2.43 | 2.57 | 3.32 | -0.98 | |
| Selling, General & Admin | 26.91 | 23.93 | 20.26 | 14.03 | 7.93 | |
| Research & Development | 58.19 | 42.8 | 33.82 | 21.95 | 12.89 | |
| Operating Expenses | 85.1 | 66.74 | 54.08 | 35.98 | 20.82 | |
| Operating Income | -51.81 | -64.3 | -51.51 | -32.66 | -21.8 | |
| Interest Expense | -1.9 | -0.3 | -1.4 | - | -0.93 | |
| Interest & Investment Income | 0.75 | 3.65 | 5.25 | 0.05 | - | |
| Other Non Operating Income (Expenses) | 0.25 | -0.01 | -0.29 | -1.35 | 0.7 | |
| EBT Excluding Unusual Items | -52.7 | -60.96 | -47.95 | -33.96 | -22.03 | |
| Gain (Loss) on Sale of Investments | - | -0.07 | -0.02 | 1.03 | -0.99 | |
| Other Unusual Items | - | - | -1.15 | -0.68 | - | |
| Pretax Income | -52.7 | -61.02 | -49.12 | -33.61 | -23.01 | |
| Net Income | -52.7 | -61.02 | -49.12 | -33.61 | -23.01 | |
| Preferred Dividends & Other Adjustments | 0.25 | - | - | - | - | |
| Net Income to Common | -52.96 | -61.02 | -49.12 | -33.61 | -23.01 | |
| Shares Outstanding (Basic) | 48 | 37 | 33 | 15 | 2 | |
| Shares Outstanding (Diluted) | 48 | 37 | 33 | 15 | 2 | |
| Shares Change (YoY) | 29.67% | 10.82% | 121.67% | 609.97% | 4.86% | |
| EPS (Basic) | -1.11 | -1.66 | -1.48 | -2.24 | -10.90 | |
| EPS (Diluted) | -1.11 | -1.66 | -1.48 | -2.24 | -10.90 | |
| Free Cash Flow | -49.45 | -50.85 | -46.21 | -29.88 | -19.7 | |
| Free Cash Flow Per Share | -1.04 | -1.38 | -1.39 | -1.99 | -9.33 | |
| Gross Margin | 99.43% | 92.27% | 93.26% | 94.03% | - | |
| Operating Margin | -154.73% | -2437.49% | -1866.16% | -924.34% | - | |
| Profit Margin | -158.16% | -2313.27% | -1779.71% | -951.26% | - | |
| Free Cash Flow Margin | -147.70% | -1927.48% | -1674.09% | -845.74% | - | |
| EBITDA | -51.48 | -63.99 | -51.22 | -32.44 | -21.62 | |
| EBITDA Margin | -153.75% | - | - | - | - | |
| D&A For EBITDA | 0.33 | 0.31 | 0.29 | 0.22 | 0.18 | |
| EBIT | -51.81 | -64.3 | -51.51 | -32.66 | -21.8 | |
| EBIT Margin | -154.73% | - | - | - | - | |
| Revenue as Reported | 33.48 | 2.64 | 2.76 | 3.53 | -0.78 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.